Don M. Benson, MD, PhD, has cared for patients at James Cancer Hospital in Ohio for 22 years, where he and his team see approximately 10,000 patient visits each year.
4, 2024 — A new study shows strong alignment between real-world outcomes and those seen in clinical trials among a broad population of patients with relapsed or refractory multiple myeloma.
Stand Up To Cancer® (SU2C) today announced a collaboration with Johnson & Johnson aimed at supporting research testing a ...
Our additional preliminary studies demonstrate that dual targeting of multiple myeloma cells and BM-CAFs by CAR-T cells is ...
News Medical on MSN1d
Scientists create an scRNA-seq atlas of the multiple myeloma immune microenvironment across disease stagesMultiple myeloma (MM) is an incurable blood cancer, leading to weakened immunity, bone damage, and other serious health ...
News Medical on MSN4d
Stand Up To Cancer partners with Johnson & Johnson to explore new treatment for AL amyloidosisStand Up To Cancer (SU2C) today announced a collaboration with Johnson & Johnson aimed at supporting research testing a combination of two types of targeted therapies, teclistamab and daratumumab, to ...
GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects multi-blockbuster ...
THRAP3, STMN1, and GNA13—are overrepresented in blood cancers like acute myeloid leukemia (AML) and could prove to be novel ...
Multiple myeloma is a rare type of cancer ... If you have kidney, heart, or liver disease and have to limit fluids, talk with your doctor before you increase the amount of fluids you drink. When you ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback